233 related articles for article (PubMed ID: 28063962)
21. Promising Outcome of Umbilical Cord Blood Transplantation in Patients with Multiple Comorbidities.
Adachi Y; Ukai S; Sagou K; Fukushima N; Ozeki K; Kohno A
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1455-1462. PubMed ID: 29476952
[TBL] [Abstract][Full Text] [Related]
22. Performance status, but not the hematopoietic cell transplantation comorbidity index (HCT-CI), predicts mortality at a Canadian transplant center.
Guilfoyle R; Demers A; Bredeson C; Richardson E; Rubinger M; Szwajcer D; Seftel MD
Bone Marrow Transplant; 2009 Jan; 43(2):133-9. PubMed ID: 18762762
[TBL] [Abstract][Full Text] [Related]
23. Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies.
Naik S; Martinez C; Leung K; Sasa G; Nguyen NY; Wu MF; Gottschalk S; Brenner M; Heslop H; Krance R
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1266-72. PubMed ID: 25765555
[TBL] [Abstract][Full Text] [Related]
24. Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: a single Japanese transplant centre study.
Kataoka K; Nannya Y; Ueda K; Kumano K; Takahashi T; Kurokawa M
Bone Marrow Transplant; 2010 Mar; 45(3):513-20. PubMed ID: 19684632
[TBL] [Abstract][Full Text] [Related]
25. Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation: a single center analysis of 389 consecutive patients.
Solh MM; Bashey A; Solomon SR; Morris LE; Zhang X; Brown S; Holland HK
Bone Marrow Transplant; 2018 May; 53(5):576-583. PubMed ID: 29335633
[TBL] [Abstract][Full Text] [Related]
26. Identifying risk factors associated with worse outcomes in adolescents and young adults undergoing hematopoietic stem cell transplantation.
Friend BD; Tang K; Markovic D; Elashoff D; Moore TB; Schiller GJ
Pediatr Blood Cancer; 2019 Dec; 66(12):e27940. PubMed ID: 31429528
[TBL] [Abstract][Full Text] [Related]
27. Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico.
Orti G; Sanz J; Bermudez A; Caballero D; Martinez C; Sierra J; Cabrera Marin JR; Espigado I; Solano C; Ferrà C; García-Noblejas A; Jimenez S; Sampol A; Yañez L; García-Gutiérrez V; Pascual MJ; Jurado M; Moraleda JM; Valcarcel D; Sanz MA; Carreras E; Duarte RF
Biol Blood Marrow Transplant; 2016 Mar; 22(3):584-8. PubMed ID: 26631751
[TBL] [Abstract][Full Text] [Related]
28. Validation of the disease risk index for outcome of patients undergoing allogeneic hematopoietic stem cell transplantation after T cell depletion.
Beauverd Y; Roosnek E; Tirefort Y; Nagy-Hulliger M; Bernimoulin M; Tsopra O; Ansari M; Dantin C; Casini A; Grandjean AP; Chigrinova E; Masouridi-Levrat S; Chalandon Y
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1322-8. PubMed ID: 24769318
[TBL] [Abstract][Full Text] [Related]
29. Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center.
Solh M; Zhang X; Connor K; Brown S; Solomon SR; Morris LE; Holland HK; Bashey A
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1403-1409. PubMed ID: 27095692
[TBL] [Abstract][Full Text] [Related]
30. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation.
Armand P; Kim HT; Logan BR; Wang Z; Alyea EP; Kalaycio ME; Maziarz RT; Antin JH; Soiffer RJ; Weisdorf DJ; Rizzo JD; Horowitz MM; Saber W
Blood; 2014 Jun; 123(23):3664-71. PubMed ID: 24744269
[TBL] [Abstract][Full Text] [Related]
31. Adjusting DLCO for Hb and its effects on the Hematopoietic Cell Transplantation-specific Comorbidity Index.
Coffey DG; Pollyea DA; Myint H; Smith C; Gutman JA
Bone Marrow Transplant; 2013 Sep; 48(9):1253-6. PubMed ID: 23503530
[TBL] [Abstract][Full Text] [Related]
32. Modified EBMT Pretransplant Risk Score Can Identify Favorable-risk Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for AML, Not Identified by the HCT-CI Score.
Michelis FV; Messner HA; Uhm J; Alam N; Lambie A; McGillis L; Seftel MD; Gupta V; Kuruvilla J; Lipton JH; Kim DD
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):e73-81. PubMed ID: 25458081
[TBL] [Abstract][Full Text] [Related]
33. Autonomic Nervous System Pretransplant Malfunction Is a Powerful Predictor of Survival After Allogeneic Hematopoietic Cell Transplantation.
Nakane T; Nakamae M; Koh H; Nishimoto M; Nakashima Y; Hirose A; Hino M; Nakamae H
Transplantation; 2017 Nov; 101(11):2801-2809. PubMed ID: 28505024
[TBL] [Abstract][Full Text] [Related]
34. Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2.
Michelis FV; Messner HA; Atenafu EG; McGillis L; Lambie A; Uhm J; Alam N; Seftel MD; Gupta V; Kuruvilla J; Lipton JH; Kim DD
Bone Marrow Transplant; 2015 Nov; 50(11):1405-10. PubMed ID: 26168067
[TBL] [Abstract][Full Text] [Related]
35. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.
Sorror ML; Storb RF; Sandmaier BM; Maziarz RT; Pulsipher MA; Maris MB; Bhatia S; Ostronoff F; Deeg HJ; Syrjala KL; Estey E; Maloney DG; Appelbaum FR; Martin PJ; Storer BE
J Clin Oncol; 2014 Oct; 32(29):3249-56. PubMed ID: 25154831
[TBL] [Abstract][Full Text] [Related]
36. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.
Sorror ML; Sandmaier BM; Storer BE; Maris MB; Baron F; Maloney DG; Scott BL; Deeg HJ; Appelbaum FR; Storb R
J Clin Oncol; 2007 Sep; 25(27):4246-54. PubMed ID: 17724349
[TBL] [Abstract][Full Text] [Related]
37. Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation.
Elsawy M; Sorror ML
Bone Marrow Transplant; 2016 Oct; 51(10):1283-1300. PubMed ID: 27272454
[TBL] [Abstract][Full Text] [Related]
38. Assessing the Influence of Different Comorbidities Indexes on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in a Developing Country.
Teixeira GM; Bittencourt H; de Macedo AV; Martinho GH; Colosimo EA; Rezende SM
PLoS One; 2015; 10(9):e0137390. PubMed ID: 26394228
[TBL] [Abstract][Full Text] [Related]
39. Replicated Risk Index of Patient Functional Status Prior to Allogeneic Hematopoietic Cell Transplantation Predicts Healthcare Utilization and Survival.
Herr MM; Rehman S; Zhang Y; Ho CM; Chen GL; Ross M; Hillengass J; Jacobson H; McKenzie R; Farrell K; Maqsood A; McCarthy PL; Hahn T
Transplant Cell Ther; 2021 Oct; 27(10):875.e1-875.e9. PubMed ID: 34216792
[TBL] [Abstract][Full Text] [Related]
40. Improved survival over the last decade in pediatric patients requiring dialysis after hematopoietic cell transplantation.
Rajpal JS; Patel N; Vogel RI; Kashtan CE; Smith AR
Biol Blood Marrow Transplant; 2013 Apr; 19(4):661-5. PubMed ID: 23266833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
